What is Pemvidutide?
Pemvidutide (development code ALT-801) is a long-acting balanced 1:1 dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). It is developed by Altimmune and is one of the leading peptide candidates in late-stage development for metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
Pemvidutide is administered as a once-weekly subcutaneous injection. It received FDA Breakthrough Therapy designation for MASH based on early evidence of profound liver-fat reduction.
Mechanism of Action
Pemvidutide is built on the oxyntomodulin (OXM) backbone — the natural human gut peptide that intrinsically activates both GLP-1R and GCGR. The molecule is engineered with:
- A modified OXM-based peptide sequence
- C20 fatty acid acylation for non-covalent albumin binding (extending half-life to once-weekly dosing)
- A balanced 1:1 ratio of GLP-1R:GCGR potency
The therapeutic logic: GLP-1 agonism produces weight loss largely through reduced food intake and slowed gastric emptying, while glucagon agonism adds an energy-expenditure component (hepatic lipolysis, thermogenesis) that further drives weight loss and dramatically improves liver fat — provided the GLP-1 component prevents the hyperglycemia that pure glucagon agonism would cause.
Pemvidutide's distinctive 1:1 ratio differs from competitors:
- Survodutide (Boehringer) — GLP-1 dominant
- Mazdutide (Innovent/Lilly, China-approved 2025) — GLP-1 dominant
- Pemvidutide — balanced 1:1 ratio, theoretically maximizing the glucagon-driven liver and energy-expenditure benefits
Clinical Evidence
MOMENTUM Phase 2 (obesity, 2024):
- 391 adults with obesity, randomized to pemvidutide 1.2 mg, 1.8 mg, or 2.4 mg weekly vs placebo
- Mean weight loss at 48 weeks: 10.3-15.6% across doses vs 2.2% placebo
- Improvements in lipids, blood pressure, liver enzymes
- Notable: significant reduction in alcohol craving and consumption (signal supporting alcohol-use-disorder development)
IMPACT Phase 2b (MASH, 2025):
- Patients with biopsy-confirmed MASH and F2-F3 fibrosis
- Pemvidutide 1.2 mg, 1.8 mg vs placebo for 48 weeks
- At 1.8 mg dose: 54.7% reduction in liver fat content (MRI-PDFF)
- 32.4% achieved ELF + LSM responder criteria vs 3.2% placebo
- Significant ALT/AST normalization
Pipeline Status
Phase 3 MASH program initiating in 2025-2026, with planned ~1,800 patient size and biopsy-based fibrosis endpoints. Phase 3 obesity program design announced.
Approval timeline (if successful): MASH NDA possibly 2027-2028; obesity NDA later.
Place in Future Therapy
If approved, pemvidutide would compete in two large markets:
- MASH — currently dominated by resmetirom (small molecule, FDA 2024) with semaglutide approved August 2025; pemvidutide's hepatic mechanism via glucagon agonism is mechanistically differentiated
- Obesity — competing with semaglutide, tirzepatide, and the Phase 3 wave (CagriSema, retatrutide, MariTide, survodutide); pemvidutide's profile may favor patients with significant hepatic steatosis
Safety Profile
Phase 2 adverse events were similar to GLP-1 class:
- Nausea, vomiting, diarrhea (dose-titration dependent)
- Modest heart rate increase
- Slight transient hyperglycemia at higher glucagon doses (offset by GLP-1 component)
The balanced glucagon component requires careful dose titration to manage glucose homeostasis, particularly in pre-diabetic or T2D populations.